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ABSTRACT: The disaccharide motif fucose-α(1-2)-gal-
actose (Fucα(1-2)Gal) is involved in many important
physiological processes, such as learning and memory,
inflammation, asthma, and tumorigenesis. However, the
size and structural complexity of Fucα(1-2)Gal-containing
glycans have posed a significant challenge to their
detection. We report a new chemoenzymatic strategy for
the rapid, sensitive detection of Fucα(1-2)Gal glycans. We
demonstrate that the approach is highly selective for the
Fucα(1-2)Gal motif, detects a variety of complex glycans
and glycoproteins, and can be used to profile the relative
abundance of the motif on live cells, discriminating
malignant from normal cells. This approach represents a
new potential strategy for biomarker detection and
expands the technologies available for understanding the
roles of this important class of carbohydrates in physiology
and disease.
Defects in glycosylation are a hallmark of many humandiseases, including autoimmune disorders, neurodegener-
ative diseases, and cancer.1 As part of a broader program to
understand the role of protein glycosylation in disease, we are
investigating the glycan motif fucose-α(1-2)-galactose (Fucα(1-
2)Gal). Fucα(1-2)Gal is found on the nonreducing terminus of
a large family of important glycans, including blood group H1
and H2, Globo H, Fuc-GM1, Lewis B, and Lewis Y. These
glycans play roles in learning and memory2 and contribute to
asthma, inflammation, and tumorigenesis.3 However, the size
and structural complexity of Fucα(1-2)Gal glycans, which range
from simple linear to large branched structures, has posed a
significant challenge to their detection and study.
Antibodies or lectins are typically used to detect glycans, but
these methods often suffer from weak binding affinity and
limited specificity, displaying cross-reactivity toward multiple
glycan epitopes.4 An alternative method, metabolic labeling,
provides a powerful and versatile approach to the detection of
glycans.5 However, metabolic labeling requires the uptake of
non-natural monosaccharide analogues into biosynthetic path-
ways, which allows for their incorporation into numerous
glycans. As a consequence, disaccharide or trisaccharide motifs
of specific sugar composition and glycosidic linkage, such as
Fucα(1-2)Gal, cannot be uniquely detected. Also, the non-
natural sugar must compete with natural sugars and thus is
often incorporated substoichiometrically into glycoconjugates,
reducing detection sensitivity. Given the diversity of carbohy-
drate structures at the cell surface, there is an urgent need to
develop new technologies for the specific detection of complex
glycans.
In this communication, we report the first strategy for the
rapid, sensitive, and selective detection of Fucα(1-2)Gal
glycans. Our approach capitalizes on the substrate tolerance
of a bacterial glycosyltransferase to covalently tag specific
glycans of interest with a non-natural sugar analogue. As the
reaction proceeds in quantitative yield, stoichiometric addition
of the non-natural sugar can be achieved, affording higher
detection sensitivity relative to antibodies, lectins, and
metabolic labeling. Although chemoenzymatic approaches
have been reported for two saccharides, O-linked-β-N-
acetylglucosamine(O-GlcNAc)6 and N-acetyllactosamine (Lac-
NAc),7 this study demonstrates the first direct detection of
complex oligosaccharides, opening up the potential to track a
broad range of physiologically important glycans.
We exploited the bacterial homologue of the human blood
group A antigen glycosyltransferase (BgtA), which transfers N-
acetylgalactosamine (GalNAc) from UDP-GalNAc onto the C-
3 position of Gal in Fucα(1-2)Gal structures.8 We reasoned
that BgtA might tolerate substitution at the C-2 position of
GalNAc, allowing for the selective tagging of Fucα(1-2)Gal
with an azido or ketone functionality (Figure 1A). To test the
approach, Fucα(1-2)Gal substrate 1 was synthesized via
reductive amination of 2′-fucosyllactose with p-nitrobenzyl-
amine and sodium cyanoborohydride (Figures 1B and S1,
Supporting Information (SI)). Indeed, treatment of 1 with
BgtA and either UDP-N-azidoacetylgalactosamine (UDP-
GalNAz, 2) or UDP-2-deoxy-2-(acetonyl)-β-D-galactopyrano-
side (UDP-ketoGal, 3) led to complete conversion to the
desired products 4 and 5, respectively, after 12 h at 4 °C, as
determined by liquid chromatography−mass spectrometry
(LC−MS; Figures 1B, S2, and S3, SI). Kinetic analysis revealed
an apparent kcat/Km value of 5.7 nM
−1 min−1 for UDP-GalNAz,
approximately 7-fold lower than the value of 40.4 nM−1 min−1
obtained for the natural UDP-GalNAc substrate (Figure S4,
SI). Subsequent reaction with an aza-dibenzo-cyclooctyne-
biotin derivative (ADIBO-biotin, 6; Figure S2, SI) using
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copper-free click chemistry (3 h, rt) or with the aminooxy-
biotin derivative 7 (Figure S2, SI; 24 h, rt) afforded the
biotinylated products 8 and 9, respectively, in quantitative yield
(Figures 1B, S2, and S3, SI).
Having demonstrated that BgtA accepts non-natural
substrates, we profiled the glycans detected by BgtA using
carbohydrate microarrays from the Consortium for Functional
Glycomics.9 Glycosylation reactions with BgtA and UDP-
GalNAz were performed on 611 different glycans simulta-
neously at three different time points. Following reaction with
ADIBO-biotin, biotinylated glycans were detected using Cy5-
conjugated streptavidin. Strong fluorescence labeling of Fucα-
(1-2)Gal structures was observed within 0.5 h (Figure 2A).
Notably, the top 26 glycans labeled contained terminal Fucα(1-
2)Gal structures, highlighting the specificity of the chemo-
enzymatic approach. Moreover, ∼91% of the terminal Fucα(1-
2)Gal containing glycans were labeled on the array, including
the H1 (68, 69) and H2 antigens (76, 77), the ganglioside Fuc-
GM1 (65), and the Globo H antigen (60), a hexasaccharide
overexpressed on breast, lung and prostate tumors3b,c and
associated with poor prognosis (Figures 2A and S5, SI).3d,e A
wide variety of linear (e.g., 501, 75, and 60) and branched
structures (e.g., 450, 362, and 457) containing the Fucα(1-
2)Gal motif were efficiently labeled (Figures 2A and S6, SI).
Modifications of the core disaccharide, such as replacing Gal
with GlcNAc, or changing the α(1-2) linkage to an α(1-3), α(1-
4), or β(1-3) linkage eliminated the enzymatic labeling by BgtA
(e.g., 80, 81, and 82; Figure S6, SI).
Consistent with a previous report,8 BgtA exhibited more
relaxed specificity toward structures appended to the reducing
end of the Gal residue. Specifically, glycans containing a β(1-
3)GalNAc, β(1-3)GlcNAc, β(1-4)GlcNAc, or β(1-4)Glc in this
position were efficiently labeled (e.g., 62, 66, 74, and 78,
respectively; Figures 2A and S5, SI). Although moderate
structural substitutions of the GlcNAc were tolerated such as 6-
O-sulfation (e.g., 501 and 222; Figure 2A), branching at this
position via α(1-3) or α(1-4) fucosylation led to weak labeling,
Figure 1. (A) Chemoenzymatic strategy for the detection of Fucα(1-
2)Gal glycans. (B) Labeling of substrate 1. LC−MS traces monitoring
the reaction progress at time 0 (top), 12 h after the addition of BgtA
and 2 (middle), and 3 h after the addition of ADIBO-biotin 6
(bottom). See SI for details.
Figure 2. (A) Time course analysis using glycan microarrays. Representative structures from the top 26 glycans with the highest relative fluorescence
intensity after 0.5 h are plotted, all of which represent terminal Fucα(1-2)Gal structures. UDP-GalNAz was omitted from some of the reactions as a
control (12 h, -UDP-GalNAz). (B) Chemoenzymatic detection of endogenous Fucα(1-2)Gal glycoproteins from neuronal lysates. (C)
Chemoenzymatic detection of Flag-tagged synapsin I expressed in HeLa cells. See SI for experimental details.
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as in the case of the Lewis B (61) and Lewis Y (72, 73)
antigens, or no appreciable labeling (e.g., 71, and 363; Figures
S5 and S7, SI). Interestingly, we also observed weak labeling of
Galβ(1-4)GlcNAc structures on the glycan array (Figure S7,
SI). However, these structures also exhibited high background
signal even in the absence of UDP-GalNAz, and BgtA failed to
label p-nitrophenyl 2-acetamido-2-deoxy-4-O-(β-D-galactopyr-
anosyl)-β-D-glucopyranoside (Galβ(1-4)GlcNAc-pNP) in sol-
ution (2 h, 25 °C), suggesting that Galβ(1-4)GlcNAc structures
are not covalently labeled by BgtA. Together, these studies
demonstrate the strong specificity of BgtA for Fucα(1-2)Gal
structures and the power of glycan microarrays to rapidly
profile the specificities of glycosyltransferases for the develop-
ment of chemoenzymatic detection strategies.
To determine whether the approach could be used to track
Fucα(1-2)Gal glycoproteins in complex cell lysates, we labeled
proteins from rat brain extracts with BgtA and UDP-GalNAz,
followed by the Cu(I)-catalyzed azide−alkyne cycloaddition
(CuAAC) reaction with tetramethyl-6-carboxyrhodamine dye
10 (alkyne-TAMRA; Figure S2, SI). We observed strong
fluorescence labeling of Fucα(1-2)Gal glycoproteins, with
minimal nonspecific labeling in the absence of BgtA, UDP-
GalNAz, or alkyne-TAMRA (Figure S8, SI). To confirm further
the specificity of the reaction, we labeled the lysates with the
alkyne-biotin derivative 11 (Figure S2, SI), captured the
biotinylated proteins using streptavidin resin, and immuno-
blotted for the presence of known Fucα(1-2)Gal glycopro-
teins.10 Neural cell adhesion molecule (NCAM), synapsin I,
and munc18-1 were all chemoenzymatically labeled and
detected in the presence, but not in the absence, of BgtA
(Figure 2B). In contrast, p44 mitogen-associated protein kinase
(p44 MAPK), a protein that has not been shown to be
fucosylated, was not detected. Glycosylated synapsin I was also
readily observed following overexpression of Flag-tagged
synapsin I in HeLa cells, chemoenzymatic labeling of the
lysates with alkyne-TAMRA, synapsin immunoprecipitation,
and visualization using an anti-TAMRA antibody (Figure 2C).
Importantly, UEAI lectin affinity chromatography failed to pull-
down and detect glycosylated synapsin I when performed on
the same scale (Figure S9, SI). Moreover, previous studies have
reported that the Fucα(1-2)Gal-specific antibody A46-B/B10
does not immunoprecipitate glycosylated synapsin I from the
same neuronal lysates.10a Thus, our chemoenzymatic approach
enables the highly sensitive detection of glycoproteins and
provides a variety of different enrichment strategies and
readouts for the Fucα(1-2)Gal motif.
We next investigated whether the chemoenzymatic strategy
could be used to image Fucα(1-2)Gal glycans in cells. HeLa
cells overexpressing Flag-tagged synapsin I were fixed,
permeabilized, and chemoenzymatically labeled on coverslips
with BgtA and UDP-GalNAz. CuAAC chemistry was then
performed using an alkyne-functionalized Alexa Fluor 488 dye
(12; Figure S2, SI) to install a fluorescent reporter onto the
Fucα(1-2)Gal glycans. Strong fluorescence labeling was
observed in cells transfected with synapsin I, and the labeling
showed excellent colocalization with intracellular synapsin I
expression (Figure 3A). No labeling of cells was observed in the
absence of BgtA, and only weak labeling of endogenous
Fucα(1-2)Gal glycoproteins was seen in the absence of
synapsin I overexpression (Figures 3A and S10, SI), confirming
the specificity of the in situ chemoenzymatic reaction.
As the Fucα(1-2)Gal epitope has been reported to be a
useful biomarker for cancer progression and prognosis,3d,e the
ability to detect Fucα(1-2)Gal glycan levels on the surface of
cancer cells would facilitate investigations into Fucα(1-2)Gal as
a diagnostic or prognostic marker and a therapeutic target for
cancer vaccines. However, antibodies and lectins that bind
Fucα(1-2)Gal have been shown to cross-react with other sugar
epitopes4a,b such as β-linked Fuc4a or recognize an incomplete
subset of Fucα(1-2)Gal glycans,4c indicating the need for more
selective, yet comprehensive, high-affinity detection methods.
We therefore applied our chemoenzymatic approach to the
detection of Fucα(1-2)Gal glycans on live cancer cells. Cells
from the human breast adenocarcinoma cell line MCF-7 were
chemoenzymatically labeled with BgtA and UDP-GalNAz for 1
h at 37 °C. After reaction with ADIBO-biotin (1 h, rt), Fucα(1-
2)Gal glycans were detected using streptavidin conjugated to
Alexa Fluor 488 dye. Membrane-associated fluorescence was
observed for cells treated with both BgtA and UDP-GalNAz,
whereas no labeling was detected for control cells labeled in the
absence of BgtA (Figure 3B).
We next compared the expression levels of Fucα(1-2)Gal
glycans across different cancer and noncancer cell lines. MCF-7
(breast cancer), MDA-mb-231 (highly invasive breast cancer),
H1299 (lung cancer), LnCAP (prostate cancer), and primary
prostrate epithelial cells (PrEC) cells were chemoenzymatically
labeled in suspension with BgtA and UDP-GalNAz (2 h, 37
°C), reacted with ADIBO-biotin (1 h, rt), and stained with the
streptavidin−Alexa Fluor 488 conjugate (20 min, 4 °C). As
shown by flow cytometry analysis, MDA-mb-231, MCF-7, and
LnCaP cells displayed the highest levels of fluorescence (Figure
4), consistent with reports of high Globo H expression on
mammary and prostate tumors.3b,c H1299 cells, a model for
nonsmall cell lung carcinoma and also reported to express
Globo H,3f showed lower Fucα(1-2)Gal expression. Impor-
tantly, flow cytometry analysis revealed a 53% increase in
Fucα(1-2)Gal expression on the surface of LnCAP cells
compared to noncancerous PrEC cells. These results
Figure 3. (A) Fluorescence detection of Fucα(1-2)Gal glycans (green)
in HeLa cells shows excellent colocalization (yellow) with Flag-tagged
synapsin I (red). No labeling was observed in the absence of BgtA.
Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue).
(B) Fluorescence detection of Fucα(1-2)Gal glycans (green) on live
MCF-7 cells. Nuclei were stained with Hoechst 342 (blue).
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demonstrate that our chemoenzymatic labeling approach can
readily discriminate cancerous cells from normal cells,
providing a new potential strategy for biomarker detection.
The method could be particularly useful for the detection of
prostate cancer from tissue biopsies, as the current standard of
PSA detection to diagnose prostate cancer has a significant
false-positive rate, leading to overtreatment.11 In addition to
histological detection, our chemoenzymatic approach could
potentially provide a new strategy to distinguish normal PSA
from tumorigenic PSA, which is reported to have higher levels
of Fucα(1-2)Gal glycosylation.12
In conclusion, we have developed a new chemoenzymatic
strategy that detects Fucα(1-2)Gal glycans with improved
efficiency and selectivity over existing methods. Our strategy
detects a variety of complex Fucα(1-2)Gal glycans and
glycoproteins and permits living cells or complex tissue extracts
to be rapidly interrogated. We anticipate that the strategy will
accelerate both the discovery of new Fucα(1-2)Gal glyco-
proteins and advance an understanding of the biological roles of
this important sugar in neurobiology and cancer. Moreover, this
study represents a proof-of-concept that chemoenzymatic
labeling strategies can be extended to more complex
oligosaccharides. Future studies will expand chemoenzymatic
detection approaches to a broad range of glycans to provide a
powerful new set of tools for glycomics research.
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Figure 4. Flow cytometry analysis of the relative expression levels of
Fucα(1-2)Gal glycans across various cancer cell lines, with comparison
to noncancerous PrEC cells. Cells were untreated (red) or
chemoenzymatically labeled in the presence (blue) or absence
(green) of BgtA. Quantification of the mean fluorescence intensity
(MFI) relative to cells labeled in the absence of BgtA is shown on the
right. Error bars represent data from duplicate (MCF-7, MDA-mb-231,
H1299) or triplicate (LnCAP, PrEC) experiments.
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